{
    "2020-07-30": [
        [
            {
                "time": "",
                "original_text": "医药生物行业日报：关注受益于海外供给收缩的血制品企业",
                "features": {
                    "keywords": [
                        "医药",
                        "生物",
                        "海外供给收缩",
                        "血制品"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "泰格将赴港！同行药明已三年涨六倍",
                "features": {
                    "keywords": [
                        "泰格",
                        "赴港",
                        "药明",
                        "三年涨六倍"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "新股认购 | 泰格医药孖展超百倍，富途认购破150亿",
                "features": {
                    "keywords": [
                        "新股认购",
                        "泰格医药",
                        "孖展",
                        "富途",
                        "150亿"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[IPO追踪]传泰格医药(03347-HK)(300347-CN)以上限定价",
                "features": {
                    "keywords": [
                        "IPO",
                        "泰格医药",
                        "上限定价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "艾德一站通：泰格医药招股仅剩一天！市传已获百倍超额认购",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "招股",
                        "百倍超额认购"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药搭上港股“顺风车”，将成为国内第三家“A+H”CRO公司",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "港股",
                        "A+H",
                        "CRO公司"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药拟将香港上市交易价格定在区间高端",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "香港上市",
                        "交易价格",
                        "区间高端"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "消息称泰格医药将提前停止香港上市交易的认购",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "香港上市",
                        "提前停止",
                        "认购"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "新冠疫苗第一股：中一签或赚17万，明天打新",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "第一股",
                        "中一签",
                        "17万",
                        "打新"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}